115 related articles for article (PubMed ID: 38917366)
1. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M; Stahl SM; Pani L; De Martin S; Cutler AJ; Maletic V; Gorodetzky CW; Vocci FJ; Sapienza FL; Kosten TR; Kröger C; Champasa P; O'Gorman C; Guidetti C; Alimonti A; Comai S; Mattarei A; Folli F; Bushnell D; Traversa S; Inturrisi CE; Manfredi PL; Pappagallo M
J Clin Psychiatry; 2024 Jun; 85(3):. PubMed ID: 38917366
[No Abstract] [Full Text] [Related]
2. Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017).
Guidetti C; De Martin S; Serra G; Apicella M; Pani L; Pappagallo M; Mattarei A; Folli F; Manfredi P; Fava M
J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38767937
[No Abstract] [Full Text] [Related]
3. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
8. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
9. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Fava M; Stahl S; Pani L; De Martin S; Pappagallo M; Guidetti C; Alimonti A; Bettini E; Mangano RM; Wessel T; de Somer M; Caron J; Vitolo OV; DiGuglielmo GR; Gilbert A; Mehta H; Kearney M; Mattarei A; Gentilucci M; Folli F; Traversa S; Inturrisi CE; Manfredi PL
Am J Psychiatry; 2022 Feb; 179(2):122-131. PubMed ID: 34933568
[No Abstract] [Full Text] [Related]
10. Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder.
Guidetti C; Serra G; Pani L; Pappagallo M; Maglio G; Martin S; Mattarei A; Folli F; Manfredi PL; Fava M
Prim Care Companion CNS Disord; 2023 Feb; 25(1):. PubMed ID: 36821775
[No Abstract] [Full Text] [Related]
11. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
Cusin C; Iovieno N; Iosifescu DV; Nierenberg AA; Fava M; Rush AJ; Perlis RH
J Clin Psychiatry; 2013 Jul; 74(7):e636-41. PubMed ID: 23945458
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
Umbricht D; Niggli M; Sanwald-Ducray P; Deptula D; Moore R; Grünbauer W; Boak L; Fontoura P
J Clin Psychiatry; 2020 Jul; 81(4):. PubMed ID: 32663909
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
Kato M; Shiosakai M; Kuwahara K; Iba K; Shimada Y; Saito M; Isogai Y; Sekine D; Aoki K; Koga N; Higuchi T
Psychiatry Clin Neurosci; 2024 Feb; 78(2):113-122. PubMed ID: 37933521
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
Liebowitz MR; Yeung PP; Entsuah R
J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
